To understand intraocular pressure (IOP) response after switching from intravitreal bevacizumab (IVB) and/or ranibizumab (IVR) to intravitreal aflibercept (IVA) for treatment-resistant neovascular age ...
The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of aflibercept than in clinical trials, according to a study published online ...
Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...
Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...
‘Rubeosis capsulare’ is an uncommon condition of neovascularisation within the lens capsule and is not amenable to conventional treatment modalities. 1 Bevacizumab, a humanised monoclonal anti-VEGF ...
Credit: Getty Images. According to the Agency, 29 reports of TASS were identified following a search of the FDA Adverse Event Reporting System database through December 19, 2019. The Food and Drug ...
SUNNYVALE, Calif., Jan. 3, 2013 -- Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic ...
A panel of ophthalmologists defined points of consensus for suprachoroidal space injections based on current published evidence. IVT is the primary method of delivering therapeutics in the eye, ...
The analysis included 41 patients who were treated with 136 intravitreal aflibercept, 8mg, injections. HealthDay News — The incidence of mild intraocular inflammation (IOI) in the real world occurs ...
“Prior to this study, we didn’t know the best treatment for persistent or recurrent macular edema, a major cause of vision loss in people with uveitis,” said Douglas A. Jabs, M.D., Johns Hopkins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results